联合化疗方案治疗晚期胃癌的临床疗效分析和安全性评估

Effect of combination of paclitaxel,cisplatin and 5-fluorouracil for treatment of advanced gastric carcinoma

目的探讨联合化疗方案PDF即紫杉醇（PTX）＋顺铂（DDP）＋5-氟尿嘧啶（5-Fu）治疗晚期胃癌的临床疗效情况和安全性。方法入选2008年1月至2010年12月期间晚期胃癌患者80例，随机分为治疗组（40例）和对照组（40例）。对照组患者采用5-Fu治疗。治疗组患者采用PTX（135mg／m^2）静脉滴注3h，第1天；DDP（25mg／m^2）静脉滴注，第1—3天；5-Fu（750mg／m^2）静脉滴注，第1～5天，28天为1个化疗周期。2个周期后分析两组患者的疗效和不良反应。结果治疗组患者中，完全缓解（CR）8例，部分缓解（PR）10例，稳定（SD）15例，进展（PD）7例，临床有效率为45．0％，临床受益率为82．5％，明显高于对照组。治疗组患者的不良反应主要是骨髓抑制和消化道反应，症状较轻，不良反应明显低于对照组。结论采用联合化疗方案治疗晚期胃癌可提高疗效，且不良反应较轻，值得临床上推广。

Objective To investigate the efficacy and toxic reaction of combination of paclitaxel, cisplantin and 5-fluorouracil for treatment of advanced gastric carcinoma. Methods Eighty patients with advanced gastric cancer were treated with PTX 150 mg/m2dropping 3 hours on day 1, DDP 20 mg/m2 dropping on day 1 to3,5-Fu 750 mg/m2 dropping on day 1 to 5. The regimen was repeated every 4 weeks. The efficacy was evaluated after 2 cycles. Results The total effective rate of test group was 82. 5% in the 40 patients with advanced gastric cancer, including 8 cases C R, 10 cases PR, 15 cases SD,7 cases PD. The main toxicity were myelosuppression and alimentary canal reactions. Conclusions The results indicate that paclitaxel combined with cisplantin and 5-fluorouracil for treatment of advanced gastric carcinoma is safe and effective. It is worthy of clinical promotion.